This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Flowserve (FLS) to Report Q3 Earnings: Beat in the Cards?
by Zacks Equity Research
Flowserve's (FLS) Q3 earnings are likely to have gained from solid backlog and strong mining, water management & specialty chemicals markets. The pandemic-led market downturn might have hurt it.
II-VI (IIVI) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
II-VI's (IIVI) Q1 results are expected to reflect gains from healthy backlog and demand for products, acquired assets and the pandemic-induced favorable trends. However, high cost and expenses might be spoilsport.
What's in Store for Axon Enterprise's (AAXN) Q3 Earnings?
by Zacks Equity Research
Axon Enterprise's (AAXN) third-quarter results are likely to reflect ongoing momentum in international revenues and strong demand for body cameras, offset by execution of lower-margin contracts.
Ball Corp (BLL) Set to Report Q3 Earnings: What to Expect?
by Zacks Equity Research
Ball Corp's (BLL) Q3 results are likely to reflect benefits from solid demand for aluminum packaging, cost-cutting actions and robust aerospace backlog.
Astec (ASTE) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Astec's (ASTE) third-quarter 2020 results are likely to reflect the impact of lower backlog and reduced capital spending at customers end.
Flowserve (FLS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Flowserve (FLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AGCO Corp (AGCO) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
AGCO Corp's (AGCO) third-quarter results likely to reflect benefits from replacement demand, as well as cost-control actions.
IDEX (IEX) Q3 Earnings and Sales Surpass Estimates, Fall Y/Y
by Zacks Equity Research
IDEX's (IEX) Q3 earnings beat estimates, while its decline from the year-ago quarter reflects the impacts of weak sales and a fall in margins. It predicts sequential improvement in Q4 organic sales.
Honeywell (HON) to Report Q3 Earnings: Will it Disappoint?
by Zacks Equity Research
Impacts of weak commercial aftermarket and original equipment businesses, coronavirus outbreak-led issues and forex woes are expected to have affected Honeywell's (HON) Q3 earnings.
Xylem (XYL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Xylem's (XYL) Q3 results are likely to reflect the adverse impacts of the pandemic on operations. Product offerings, impressive backlog and savings from cost actions are expected to have aided.
Altra Industrial (AIMC) Beats on Q3 Earnings, Hikes '20 View
by Zacks Equity Research
Altra Industrial's (AIMC) Q3 earnings reflect gains from cost management and improved margins that more than offset the decline in sales. It increases the 2020 projections and hikes the dividend rate.
Fortune Brands (FBHS) to Post Q3 Earnings: Beat in Store?
by Zacks Equity Research
Strong demand for decking products and solid momentum in its doors and security businesses, and strength across its plumbing business are expected to have boosted Fortune Brands' (FBHS) Q3 results.
FLS vs. XYL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
FLS vs. XYL: Which Stock Is the Better Value Option?
Illinois Tool (ITW) Q3 Earnings Beat Estimates, Decline Y/Y
by Zacks Equity Research
Illinois Tool's (ITW) Q3 earnings reflect the impacts of weak revenue generation, a fall in the operating margin and benefits from enterprise initiatives. It refrains from reinstating 2020 projections.
Stanley Black (SWK) to Post Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Stanley Black's (SWK) Q3 results are expected to reflect gains from improving product demand, rise in the e-commerce business and cost-saving moves. Forex woes and tariffs are likely to have hurt.
Roper (ROP) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Roper's (ROP) third-quarter 2020 earnings are likely to have gained from strong network software and medical products. Weak upstream oil and gas businesses are expected to have hurt results.
Illinois Tool (ITW) to Post Q3 Earnings: Beat in the Cards?
by Zacks Equity Research
Illinois Tool (ITW) Q3 earnings might have gained from strength in consumer packaging businesses, solid product offerings and focus on supply-chain management despite the pandemic-led market downturn.
iRobot (IRBT) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
iRobot's (IRBT) Q3 results might reflect a healthy demand for products, a surge in e-commerce and improved international businesses. Pandemic woes and promotional expenses are to ail.
Parker-Hannifin (PH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Parker-Hannifin (PH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Income Stocks to Buy for October 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 16th.
Middleby Stock Up 26.4% in 3 Months: What's Driving it?
by Zacks Equity Research
Middleby (MIDD) stands to benefit from a strong product portfolio, improving order trends, solid backlog and acquisitions. However, its debt level remains high.
Top Ranked Income Stocks to Buy for October 15th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 15th.
Tetra Tech Secures $24M Single-Award Contract From USAID
by Zacks Equity Research
Tetra Tech's (TTEK) contract with USAID will help the latter in executing the Regional Water and Vulnerable Environment Activity in Central Asia.
Parker-Hannifin Gains From Acquisitions Amid Pandemic Scare
by Zacks Equity Research
Parker-Hannifin (PH) is likely to benefit from strength across its end markets and acquired assets. The coronavirus outbreak-led market downturn and high debt level pose concerns.
Reasons Why it is Worth Investing in Colfax (CFX) Stock Now
by Zacks Equity Research
Colfax (CFX) to benefit from growth opportunities in the Fabrication Technology and Medical Technology segments. Also, business in multiple end markets and cost-reduction actions are other tailwinds.